Resolution of Liver Cirrhosis and Prevention of Hepatocellular Carcinoma by Interferon Therapy against Chronic Hepatitis C

References

• Shiratori Y, Shiina S, Imamura M, Kato N, Kanai F, Okudaira T, et al. Characteristic difference of hepatocellular carcinoma between hepatitis-B and -C viral infection in Japan. Hepatology 1995;22:1027–33.
   PubMed Web of Science ®Google Scholar
• Di Bisceglie AM, Goodman ZD, Ishak KG, et al. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology 1991;14:969–74.
   PubMed Web of Science ®Google Scholar
• Seef LB, Buskell-ales Z, Wright EG, et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med 1992;327:1906–11.
   PubMed Web of Science ®Google Scholar
• Tong MJ, Neveen S, El-Farra NS, et al. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332: 1463–6.
   Google Scholar
• Fattovich G, Giusta G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463–72.
   PubMed Web of Science ®Google Scholar
• De Bisceglie AM, Goodman ZD, Ishak KG, et al. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology 1991;14:969–74.
   PubMed Web of Science ®Google Scholar
• Takano S, Yokosuka O, Imazeki F, Tagawa M, Omata M. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology 1995; 21: 650–5.
   Google Scholar
• Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 1997;336:1855–9.
   PubMed Web of Science ®Google Scholar
• Desmet VJ, Gerber M, Hoofnagle JH, et al. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994;19:1513–20.
   PubMed Web of Science ®Google Scholar
• Bedossa P, Poynard T, for the METAVIR., An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996;24: 289–93.
   PubMed Web of Science ®Google Scholar
• The French METAVIR cooperative study group., Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994;20:15–20.
   PubMed Web of Science ®Google Scholar
• Omata M. ‘Live’ Discussion on New Classification of Chronic Hepatitis. Tokyo: Churchill Livingstone; 1996. p. 1–79.
   Google Scholar
• Poynard T, Bedossa P, Oplon P, for the OBSTiRc, METAVIR, CLINIVIR, and DOSVIRC groups., Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997;349: 825–32.
   Google Scholar
• Mathurin P, Moussalli J, Cadranel JF, et al. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology 1998;27:868–72.
   PubMed Web of Science ®Google Scholar
• Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000;132:517–24.
   PubMed Web of Science ®Google Scholar
• Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997;336:347–56.
   PubMed Web of Science ®Google Scholar
• Yokosuka O, Kato N, Hosoda K, Ito Y, Imazeki F, Ohto M, et al. Efficacy of long-term interferon treatment in chronic liver disease evaluated by sensitive polymerase chain reaction assay for hepatitis C virus RNA. Gut 1995;37:721–6.
   PubMed Web of Science ®Google Scholar
• Lau JYM, Davis GL, Kniffen J, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993;341:1501–4.
   PubMed Web of Science ®Google Scholar
• Shiratori Y, Kato N, Yokosuka O, et al. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Gastroenterology 1997;113:558–66.
   PubMed Web of Science ®Google Scholar
• Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996;24:778–89.
   PubMed Web of Science ®Google Scholar
• Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program in Japan of cirrhotic and non-cirrhotic patients with chronic hepatitis C. Ann Intern Med 1999;131:174–81.
   PubMed Web of Science ®Google Scholar
• Omata M, Iwama S, Sumida S, Ito Y, Okuda K. Clinicopathological study of acute non-A, non-B post-transfusion hepatitis, histological features of liver biopsies in acute phase. Liver 1981;1:201–8.
   Google Scholar
• Reichard O, Glaumann H, Fryden A, et al. Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment. Hepatology 1995;21:918–22.
   PubMed Web of Science ®Google Scholar
• Manesis EK, Papaioannou C, Gioustozi A, et al. Biochemical nd virological outcome of patients with chronic hepatitis C treated with interferon alfa-2b for 6 or 12 months: a 4-year follow-up of 211 patients. Hepatology 1997;26:734–9.
   PubMedGoogle Scholar
• Sobesky R, Mathurin P, Charlotte F, et al. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. Gastroenterology 1999; 116:378–86.
   PubMed Web of Science ®Google Scholar
• Lau DTY, Kleiner DE, Ghany MG, et al. 10-year follow-up after interferon-alfa therapy for chronic hepatitis C. Hepatology 1998; 28:1121–7.
   PubMed Web of Science ®Google Scholar
• Marcellin P, Boyer N, Gervais A, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alfa therapy. Ann Intern Med 127:875–81.
   Google Scholar